Only recently was SB-216763, a GSK-3β inhibitor, identified to both prevent and reverse ARVC in mice by targeting a specific interaction between AnkB and β-catenin through the Wnt signaling pathway [27], but this therapeutic strategy has not yet been tested. The gene discussed is ANK2; the disease is Arrhythmogenic right ventricular dysplasia.